Dr. Tagawa discusses the FDA approval of sacituzumab govitecan in urothelial cancer, key efficacy and safety data from the pivotal TROPHY-U-01 trial, and expectations for the confirmatory TROPiCS-04 trial.
Please enable it in your browser's preferences.
You can visit our support center if you're having problems.
We recommend upgrading to the latest
Please check your internet connection and refresh the page. You might also try disabling any ad blockers.